Business
Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display
Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONSFor the first time, Bionano will exhibit all of its
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONSFor the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location] Optical Genome Mapping Solutions,Testing and Laboratory Services, &Software Six scientific posters will illustrate the capabilities and scope of Bionano’s solutions for impacting clinical genetics research and rare undiagnosed genetic diseases (RUGD) SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that it is participating in-person at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. In addition to having six posters that present advances in clinical genetics research, Bionano will exhibit its complete portfolio of products and services as one company with more solutions. The main ACMG conference sessions take place from March 23–26, 2022, in Nashville, TN with a virtual attendance option. As the first major genetics conference to be held in person in the U.S. since 2020, Bionano’s commercial presence will reflect its expansion over the last two years, which now includes genome mapping solutions, software, and testing and laboratory services. Bionano acquired BioDiscovery in November 2021 and has integrated BioDiscovery’s software products into its commercial offering while the combined software development teams focus on adding OGM data alongside sequencing and microarray data in NxClinical™ under the leadership of Dr. Soheil Shams, Bionano’s Chief Informatics Officer and founder of BioDiscovery. Bionano acquired Lineagen in August 2020 and sells Lineagen’s menu of laboratory developed tests (LDTs) for pediatric neurodevelopmental disorders, including autism spectrum disorder. Bionano will have multiple attendees participating from both the scientific and commercial teams representing all product categories. “Bionano has evolved significantly in the last two years and we are now one team with more solutions that can benefit genetic clinicians and researchers. We believe our solutions can promote discovery by enablin...